| Year |
Citation |
Score |
| 2019 |
Luo D, DiGiovanni MG, Wei R, LaComb JF, Williams JL, Rigas B, Mackenzie GG. Phospho-valproic acid (MDC-1112) reduces pancreatic cancer growth in patient-derived tumor xenografts and KPC mice: enhanced efficacy when combined with gemcitabine. Carcinogenesis. PMID 31584613 DOI: 10.1093/Carcin/Bgz170 |
0.471 |
|
| 2019 |
Luo D, Fraga-Lauhirat M, Millings J, Ho C, Villarreal EM, Fletchinger TC, Bonfiglio JV, Mata L, Nemesure MD, Bartels LE, Wang R, Rigas B, Mackenzie GG. Phospho-valproic acid (MDC-1112) suppresses glioblastoma growth in preclinical models through the inhibition of STAT3 phosphorylation. Carcinogenesis. PMID 30994173 DOI: 10.1093/Carcin/Bgz069 |
0.444 |
|
| 2018 |
Kathawala RJ, Kudelka A, Rigas B. Correction: The Chemoprevention of Ovarian Cancer: the Need and the Options. Current Pharmacology Reports. 4: 414. PMID 31187022 DOI: 10.1007/S40495-018-0159-9 |
0.378 |
|
| 2018 |
Kathawala RJ, Kudelka A, Rigas B. The Chemoprevention of Ovarian Cancer: the Need and the Options. Current Pharmacology Reports. 4: 250-260. PMID 30363743 DOI: 10.1007/S40495-018-0133-6 |
0.411 |
|
| 2018 |
Mattheolabakis G, Wang R, Rigas B, Mackenzie GG. [Corrigendum] Phospho‑valproic acid inhibits pancreatic cancer growth in mice: Enhanced efficacy by its formulation in poly‑(L)‑lactic acid‑poly(ethylene glycol) nanoparticles. International Journal of Oncology. PMID 30320367 DOI: 10.3892/Ijo.2018.4584 |
0.355 |
|
| 2018 |
Honkanen RA, Huang L, Xie G, Rigas B. Phosphosulindac is efficacious in an improved concanavalin A-based rabbit model of chronic dry eye disease. Translational Research : the Journal of Laboratory and Clinical Medicine. PMID 29702077 DOI: 10.1016/J.Trsl.2018.04.002 |
0.308 |
|
| 2017 |
Mattheolabakis G, Wang R, Rigas B, Mackenzie GG. Phospho-valproic acid inhibits pancreatic cancer growth in mice: enhanced efficacy by its formulation in poly-(L)-lactic acid-poly(ethylene glycol) nanoparticles. International Journal of Oncology. PMID 28849098 DOI: 10.3892/Ijo.2017.4103 |
0.414 |
|
| 2016 |
Mattheolabakis G, Papayannis I, Yang J, Vaeth BM, Wang R, Bandovic J, Ouyang N, Rigas B, Mackenzie GG. Phospho-aspirin (MDC-22) prevents pancreatic carcinogenesis in mice. Cancer Prevention Research (Philadelphia, Pa.). PMID 27138793 DOI: 10.1158/1940-6207.Capr-15-0344 |
0.423 |
|
| 2016 |
Bartels LE, Mattheolabakis G, Vaeth BM, LaComb JF, Wang R, Zhi J, Komninou D, Rigas B, Mackenzie GG. The novel agent phospho-glycerol-ibuprofen-amide (MDC-330) inhibits glioblastoma growth in mice: an effect mediated by cyclin D1. Carcinogenesis. PMID 26905586 DOI: 10.1093/Carcin/Bgw017 |
0.41 |
|
| 2015 |
Tsioulias GJ, Go MF, Rigas B. NSAIDs and Colorectal Cancer Control: Promise and Challenges. Current Pharmacology Reports. 1: 295-301. PMID 26688785 DOI: 10.1007/S40495-015-0042-X |
0.398 |
|
| 2015 |
Rigas B, Tsioulias GJ. The evolving role of nonsteroidal anti-inflammatory drugs in colon cancer prevention: a cause for optimism. The Journal of Pharmacology and Experimental Therapeutics. 353: 2-8. PMID 25589413 DOI: 10.1124/Jpet.114.220806 |
0.417 |
|
| 2015 |
Pulkoski-Gross A, Li J, Zheng C, Li Y, Ouyang N, Rigas B, Zucker S, Cao J. Repurposing the antipsychotic trifluoperazine as an antimetastasis agent. Molecular Pharmacology. 87: 501-12. PMID 25552486 DOI: 10.1124/mol.114.096941 |
0.358 |
|
| 2015 |
Wong CC, Cheng KW, Papayannis I, Mattheolabakis G, Huang L, Xie G, Ouyang N, Rigas B. Phospho-NSAIDs have enhanced efficacy in mice lacking plasma carboxylesterase: implications for their clinical pharmacology. Pharmaceutical Research. 32: 1663-75. PMID 25392229 DOI: 10.1007/S11095-014-1565-2 |
0.305 |
|
| 2014 |
Huang L, Wong CC, Cheng KW, Rigas B. Phospho-aspirin-2 (MDC-22) inhibits estrogen receptor positive breast cancer growth both in vitro and in vivo by a redox-dependent effect. Plos One. 9: e111720. PMID 25369051 DOI: 10.1371/Journal.Pone.0111720 |
0.476 |
|
| 2014 |
Cheng KW, Nie T, Ouyang N, Alston N, Wong CC, Mattheolabakis G, Papayannis I, Huang L, Rigas B. A novel ibuprofen derivative with anti-lung cancer properties: synthesis, formulation, pharmacokinetic and efficacy studies. International Journal of Pharmaceutics. 477: 236-43. PMID 25311177 DOI: 10.1016/J.Ijpharm.2014.10.019 |
0.455 |
|
| 2014 |
Mattheolabakis G, Wong CC, Sun Y, Amella CA, Richards R, Constantinides PP, Rigas B. Pegylation improves the pharmacokinetics and bioavailability of small-molecule drugs hydrolyzable by esterases: a study of phospho-Ibuprofen. The Journal of Pharmacology and Experimental Therapeutics. 351: 61-6. PMID 25047517 DOI: 10.1124/Jpet.114.217208 |
0.482 |
|
| 2014 |
Xie G, Cheng KW, Huang L, Rigas B. The in vitro metabolism of phospho-sulindac amide, a novel potential anticancer agent. Biochemical Pharmacology. 91: 249-55. PMID 25044307 DOI: 10.1016/J.Bcp.2014.07.007 |
0.369 |
|
| 2014 |
Huang L, Wong CC, Mackenzie GG, Sun Y, Cheng KW, Vrankova K, Alston N, Ouyang N, Rigas B. Phospho-aspirin (MDC-22) inhibits breast cancer in preclinical animal models: an effect mediated by EGFR inhibition, p53 acetylation and oxidative stress. Bmc Cancer. 14: 141. PMID 24575839 DOI: 10.1186/1471-2407-14-141 |
0.433 |
|
| 2014 |
Murray OT, Wong CC, Vrankova K, Rigas B. Phospho-sulindac inhibits pancreatic cancer growth: NFATc1 as a drug resistance candidate. International Journal of Oncology. 44: 521-9. PMID 24284479 DOI: 10.3892/Ijo.2013.2190 |
0.781 |
|
| 2013 |
Mackenzie GG, Bartels LE, Xie G, Papayannis I, Alston N, Vrankova K, Ouyang N, Rigas B. A novel Ras inhibitor (MDC-1016) reduces human pancreatic tumor growth in mice. Neoplasia (New York, N.Y.). 15: 1184-95. PMID 24204197 DOI: 10.1593/Neo.131368 |
0.509 |
|
| 2013 |
Cheng KW, Wong CC, Mattheolabakis G, Xie G, Huang L, Rigas B. Curcumin enhances the lung cancer chemopreventive efficacy of phospho-sulindac by improving its pharmacokinetics. International Journal of Oncology. 43: 895-902. PMID 23807084 DOI: 10.3892/Ijo.2013.1995 |
0.486 |
|
| 2013 |
Mackenzie GG, Huang L, Alston N, Ouyang N, Vrankova K, Mattheolabakis G, Constantinides PP, Rigas B. Targeting mitochondrial STAT3 with the novel phospho-valproic acid (MDC-1112) inhibits pancreatic cancer growth in mice. Plos One. 8: e61532. PMID 23650499 DOI: 10.1371/Journal.Pone.0061532 |
0.469 |
|
| 2013 |
Cheng KW, Wong CC, Alston N, Mackenzie GG, Huang L, Ouyang N, Xie G, Wiedmann T, Rigas B. Aerosol administration of phospho-sulindac inhibits lung tumorigenesis. Molecular Cancer Therapeutics. 12: 1417-28. PMID 23645590 DOI: 10.1158/1535-7163.Mct-13-0006-T |
0.402 |
|
| 2013 |
Mattheolabakis G, Mackenzie GG, Huang L, Ouyang N, Cheng KW, Rigas B. Topically applied phospho-sulindac hydrogel is efficacious and safe in the treatment of experimental arthritis in rats. Pharmaceutical Research. 30: 1471-82. PMID 23483440 DOI: 10.1007/S11095-012-0953-8 |
0.327 |
|
| 2013 |
Xie G, Zhou D, Cheng KW, Wong CC, Rigas B. Comparative in vitro metabolism of phospho-tyrosol-indomethacin by mice, rats and humans. Biochemical Pharmacology. 85: 1195-202. PMID 23399640 DOI: 10.1016/J.Bcp.2013.01.031 |
0.34 |
|
| 2013 |
Zhou D, Papayannis I, Mackenzie GG, Alston N, Ouyang N, Huang L, Nie T, Wong CC, Rigas B. The anticancer effect of phospho-tyrosol-indomethacin (MPI-621), a novel phosphoderivative of indomethacin: in vitro and in vivo studies. Carcinogenesis. 34: 943-51. PMID 23338686 DOI: 10.1093/Carcin/Bgs394 |
0.495 |
|
| 2013 |
Mironava T, Simon M, Rafailovich MH, Rigas B. Platinum folate nanoparticles toxicity: cancer vs. normal cells. Toxicology in Vitro : An International Journal Published in Association With Bibra. 27: 882-9. PMID 23318730 DOI: 10.1016/J.Tiv.2013.01.005 |
0.381 |
|
| 2012 |
Mattheolabakis G, Rigas B, Constantinides PP. Nanodelivery strategies in cancer chemotherapy: biological rationale and pharmaceutical perspectives. Nanomedicine (London, England). 7: 1577-90. PMID 23148540 DOI: 10.2217/Nnm.12.128 |
0.356 |
|
| 2012 |
Ouyang N, Zhu C, Zhou D, Nie T, Go MF, Richards RJ, Rigas B. MC-12, an annexin A1-based peptide, is effective in the treatment of experimental colitis. Plos One. 7: e41585. PMID 22844504 DOI: 10.1371/Journal.Pone.0041585 |
0.319 |
|
| 2012 |
Cheng KW, Mattheolabakis G, Wong CC, Ouyang N, Huang L, Constantinides PP, Rigas B. Topical phospho-sulindac (OXT-328) is effective in the treatment of non-melanoma skin cancer. International Journal of Oncology. 41: 1199-203. PMID 22842609 DOI: 10.3892/Ijo.2012.1577 |
0.429 |
|
| 2012 |
Xie G, Wong CC, Cheng KW, Huang L, Constantinides PP, Rigas B. In vitro and in vivo metabolic studies of phospho-aspirin (MDC-22). Pharmaceutical Research. 29: 3292-301. PMID 22782648 DOI: 10.1007/S11095-012-0821-6 |
0.41 |
|
| 2012 |
Zhu R, Cheng KW, Mackenzie G, Huang L, Sun Y, Xie G, Vrankova K, Constantinides PP, Rigas B. Phospho-sulindac (OXT-328) inhibits the growth of human lung cancer xenografts in mice: enhanced efficacy and mitochondria targeting by its formulation in solid lipid nanoparticles. Pharmaceutical Research. 29: 3090-101. PMID 22723123 DOI: 10.1007/S11095-012-0801-X |
0.395 |
|
| 2012 |
Zhu C, Cheng KW, Ouyang N, Huang L, Sun Y, Constantinides P, Rigas B. Phosphosulindac (OXT-328) selectively targets breast cancer stem cells in vitro and in human breast cancer xenografts. Stem Cells (Dayton, Ohio). 30: 2065-75. PMID 22653497 DOI: 10.1002/Stem.1139 |
0.399 |
|
| 2012 |
Xie G, Wong CC, Cheng KW, Huang L, Constantinides PP, Rigas B. Regioselective oxidation of phospho-NSAIDs by human cytochrome P450 and flavin monooxygenase isoforms: implications for their pharmacokinetic properties and safety. British Journal of Pharmacology. 167: 222-32. PMID 22489789 DOI: 10.1111/J.1476-5381.2012.01982.X |
0.447 |
|
| 2012 |
Wong CC, Cheng KW, Rigas B. Preclinical predictors of anticancer drug efficacy: critical assessment with emphasis on whether nanomolar potency should be required of candidate agents. The Journal of Pharmacology and Experimental Therapeutics. 341: 572-8. PMID 22448039 DOI: 10.1124/Jpet.112.191957 |
0.441 |
|
| 2012 |
Sun Y, Rowehl LM, Huang L, Mackenzie GG, Vrankova K, Komninou D, Rigas B. Phospho-ibuprofen (MDC-917) suppresses breast cancer growth: an effect controlled by the thioredoxin system. Breast Cancer Research : Bcr. 14: R20. PMID 22293394 DOI: 10.1186/Bcr3105 |
0.46 |
|
| 2012 |
Nie T, Wong CC, Alston N, Aro P, Constantinides PP, Rigas B. Phospho-ibuprofen (MDC-917) incorporated in nanocarriers: anti-cancer activity in vitro and in vivo. British Journal of Pharmacology. 166: 991-1001. PMID 22141583 DOI: 10.1111/J.1476-5381.2011.01799.X |
0.528 |
|
| 2012 |
Wong CC, Cheng KW, Xie G, Zhou D, Zhu CH, Constantinides PP, Rigas B. Carboxylesterases 1 and 2 hydrolyze phospho-nonsteroidal anti-inflammatory drugs: relevance to their pharmacological activity. The Journal of Pharmacology and Experimental Therapeutics. 340: 422-32. PMID 22085648 DOI: 10.1124/Jpet.111.188508 |
0.46 |
|
| 2012 |
Mattheolabakis G, Nie T, Constantinides PP, Rigas B. Sterically stabilized liposomes incorporating the novel anticancer agent phospho-ibuprofen (MDC-917): preparation, characterization, and in vitro/in vivo evaluation. Pharmaceutical Research. 29: 1435-43. PMID 22072052 DOI: 10.1007/S11095-011-0619-Y |
0.425 |
|
| 2012 |
Xie G, Nie T, Mackenzie GG, Sun Y, Huang L, Ouyang N, Alston N, Zhu C, Murray OT, Constantinides PP, Kopelovich L, Rigas B. The metabolism and pharmacokinetics of phospho-sulindac (OXT-328) and the effect of difluoromethylornithine. British Journal of Pharmacology. 165: 2152-66. PMID 21955327 DOI: 10.1111/J.1476-5381.2011.01705.X |
0.744 |
|
| 2012 |
Murray OT, Vrankova K, Johnson F, Rigas B. Abstract 4431: NFATc1 silencing increases sensitivity of pancreatic cancer cells to phosphosulindac Cancer Research. 72: 4431-4431. DOI: 10.1158/1538-7445.Am2012-4431 |
0.78 |
|
| 2012 |
Williams JL, Ji P, Ouyang N, Kopelovich L, Rigas B. Corrigendum to "Protein nitration and nitrosylation by NO-donating aspirin in colon cancer cells: Relevance to its mechanism of action" [Exp Cell Res 314 (2011) 1359-1367] Experimental Cell Research. 318: 1185. DOI: 10.1016/J.Yexcr.2012.04.001 |
0.448 |
|
| 2011 |
Huang L, Mackenzie GG, Sun Y, Ouyang N, Xie G, Vrankova K, Komninou D, Rigas B. Chemotherapeutic properties of phospho-nonsteroidal anti-inflammatory drugs, a new class of anticancer compounds. Cancer Research. 71: 7617-27. PMID 22025561 DOI: 10.1158/0008-5472.Can-11-2349 |
0.493 |
|
| 2011 |
Joseph S, Nie T, Huang L, Zhou H, Atmakur K, Gupta RC, Johnson F, Rigas B. Structure-activity relationship study of novel anticancer aspirin-based compounds. Molecular Medicine Reports. 4: 891-9. PMID 21805049 DOI: 10.3892/Mmr.2011.534 |
0.664 |
|
| 2011 |
Sun Y, Huang L, Mackenzie GG, Rigas B. Oxidative stress mediates through apoptosis the anticancer effect of phospho-nonsteroidal anti-inflammatory drugs: implications for the role of oxidative stress in the action of anticancer agents. The Journal of Pharmacology and Experimental Therapeutics. 338: 775-83. PMID 21646387 DOI: 10.1124/Jpet.111.183533 |
0.423 |
|
| 2011 |
Mackenzie GG, Ouyang N, Xie G, Vrankova K, Huang L, Sun Y, Komninou D, Kopelovich L, Rigas B. Phospho-sulindac (OXT-328) combined with difluoromethylornithine prevents colon cancer in mice. Cancer Prevention Research (Philadelphia, Pa.). 4: 1052-60. PMID 21464038 DOI: 10.1158/1940-6207.Capr-11-0067 |
0.452 |
|
| 2011 |
Xie G, Sun Y, Nie T, Mackenzie GG, Huang L, Kopelovich L, Komninou D, Rigas B. Phospho-ibuprofen (MDC-917) is a novel agent against colon cancer: efficacy, metabolism, and pharmacokinetics in mouse models. The Journal of Pharmacology and Experimental Therapeutics. 337: 876-86. PMID 21422165 DOI: 10.1124/Jpet.111.180224 |
0.46 |
|
| 2011 |
Williams JL, Ji P, Ouyang N, Kopelovich L, Rigas B. Protein nitration and nitrosylation by NO-donating aspirin in colon cancer cells: Relevance to its mechanism of action. Experimental Cell Research. 317: 1359-67. PMID 21406194 DOI: 10.1016/J.Yexcr.2011.03.001 |
0.481 |
|
| 2010 |
Huang L, Zhu C, Sun Y, Xie G, Mackenzie GG, Qiao G, Komninou D, Rigas B. Phospho-sulindac (OXT-922) inhibits the growth of human colon cancer cell lines: a redox/polyamine-dependent effect. Carcinogenesis. 31: 1982-90. PMID 20627873 DOI: 10.1093/Carcin/Bgq149 |
0.52 |
|
| 2010 |
Mackenzie GG, Sun Y, Huang L, Xie G, Ouyang N, Gupta RC, Johnson F, Komninou D, Kopelovich L, Rigas B. Phospho-sulindac (OXT-328), a novel sulindac derivative, is safe and effective in colon cancer prevention in mice. Gastroenterology. 139: 1320-32. PMID 20600034 DOI: 10.1053/J.Gastro.2010.06.044 |
0.505 |
|
| 2010 |
Zhang Z, Huang L, Zhao W, Rigas B. Annexin 1 induced by anti-inflammatory drugs binds to NF-kappaB and inhibits its activation: anticancer effects in vitro and in vivo. Cancer Research. 70: 2379-88. PMID 20215502 DOI: 10.1158/0008-5472.Can-09-4204 |
0.462 |
|
| 2010 |
Joseph SJ, Nie T, Johnson F, Gupta R, Rigas B. Abstract 745: Structure-activity relationship study of the novel aspirin-based anticancer compounds Cancer Research. 70: 745-745. DOI: 10.1158/1538-7445.Am10-745 |
0.682 |
|
| 2010 |
Caihua Z, Huang L, Sun Y, Xie G, Mackenzie G, Komninou D, Rigas B. Abstract 4468: A novel sulindac derivative (MDC-922) inhibits the growth of human colon cancer cell lines: A redox/polyamine-dependent effect Cancer Research. 70: 4468-4468. DOI: 10.1158/1538-7445.Am10-4468 |
0.541 |
|
| 2010 |
Wang Y, Zhang Z, Jain V, Yi J, Mueller S, Sokolov J, Liu Z, Levon K, Rigas B, Rafailovich MH. Potentiometric sensors based on surface molecular imprinting: Detection of cancer biomarkers and viruses Sensors and Actuators, B: Chemical. 146: 381-387. DOI: 10.1016/J.Snb.2010.02.032 |
0.323 |
|
| 2009 |
Hua A, Mackenzie GG, Rigas B. The differential cell signaling effects of two positional isomers of the anticancer NO-donating aspirin. International Journal of Oncology. 35: 837-44. PMID 19724920 DOI: 10.3892/Ijo_00000397 |
0.439 |
|
| 2009 |
Foreman JE, Sorg JM, McGinnis KS, Rigas B, Williams JL, Clapper ML, Gonzalez FJ, Peters JM. Regulation of peroxisome proliferator-activated receptor-beta/delta by the APC/beta-CATENIN pathway and nonsteroidal antiinflammatory drugs. Molecular Carcinogenesis. 48: 942-52. PMID 19415698 DOI: 10.1002/Mc.20546 |
0.339 |
|
| 2009 |
Zhao W, Mackenzie GG, Murray OT, Zhang Z, Rigas B. Phosphoaspirin (MDC-43), a novel benzyl ester of aspirin, inhibits the growth of human cancer cell lines more potently than aspirin: a redox-dependent effect. Carcinogenesis. 30: 512-9. PMID 19136474 DOI: 10.1093/Carcin/Bgp015 |
0.775 |
|
| 2009 |
Sun Y, Chen J, Rigas B. Chemopreventive agents induce oxidative stress in cancer cells leading to COX-2 overexpression and COX-2-independent cell death. Carcinogenesis. 30: 93-100. PMID 18952595 DOI: 10.1093/Carcin/Bgn242 |
0.4 |
|
| 2009 |
Zhou H, Huang L, Sun Y, Rigas B. Nitric oxide-donating aspirin inhibits the growth of pancreatic cancer cells through redox-dependent signaling. Cancer Letters. 273: 292-9. PMID 18805632 DOI: 10.1016/J.Canlet.2008.08.006 |
0.489 |
|
| 2008 |
Rigas B, Rao CV, Cooney R, Singh S. Food components, alternative medicine, and cancer: progress and promise. Nutrition and Cancer. 60: 1. PMID 19003574 DOI: 10.1080/01635580802393134 |
0.432 |
|
| 2008 |
Sun Y, Rigas B. The thioredoxin system mediates redox-induced cell death in human colon cancer cells: implications for the mechanism of action of anticancer agents. Cancer Research. 68: 8269-77. PMID 18922898 DOI: 10.1158/0008-5472.Can-08-2010 |
0.464 |
|
| 2008 |
Yang K, Kurihara N, Fan K, Newmark H, Rigas B, Bancroft L, Corner G, Livote E, Lesser M, Edelmann W, Velcich A, Lipkin M, Augenlicht L. Dietary induction of colonic tumors in a mouse model of sporadic colon cancer. Cancer Research. 68: 7803-10. PMID 18829535 DOI: 10.1158/0008-5472.Can-08-1209 |
0.445 |
|
| 2008 |
Rao CV, Joseph S, Gao L, Patlolla JM, Choi CI, Kopelovich L, Steele VE, Rigas B. Pharmacokinetic and pharmacodynamic study of NO-donating aspirin in F344 rats. International Journal of Oncology. 33: 799-805. PMID 18813794 DOI: 10.3892/Ijo_00000067 |
0.588 |
|
| 2008 |
Ouyang N, Williams JL, Rigas B. NO-donating aspirin inhibits angiogenesis by suppressing VEGF expression in HT-29 human colon cancer mouse xenografts. Carcinogenesis. 29: 1794-8. PMID 18544566 DOI: 10.1093/Carcin/Bgn127 |
0.413 |
|
| 2008 |
Mackenzie GG, Rasheed S, Wertheim W, Rigas B. NO-Donating NSAIDs, PPARdelta, and Cancer: Does PPARdelta Contribute to Colon Carcinogenesis? Ppar Research. 2008: 919572. PMID 18528523 DOI: 10.1155/2008/919572 |
0.501 |
|
| 2008 |
Rasheed S, Rigas B. Screening for colorectal cancer: does it all start with aberrant crypt foci? Gastrointestinal Endoscopy. 67: 1103-5. PMID 18513552 DOI: 10.1016/J.Gie.2007.10.038 |
0.374 |
|
| 2008 |
Rigas B, Williams JL. NO-donating NSAIDs and cancer: an overview with a note on whether NO is required for their action. Nitric Oxide : Biology and Chemistry / Official Journal of the Nitric Oxide Society. 19: 199-204. PMID 18486630 DOI: 10.1016/J.Niox.2008.04.022 |
0.493 |
|
| 2008 |
Rigas B, Sun Y. Induction of oxidative stress as a mechanism of action of chemopreventive agents against cancer British Journal of Cancer. 98: 1157-1160. PMID 18253125 DOI: 10.1038/Sj.Bjc.6604225 |
0.445 |
|
| 2008 |
Williams JL, Ji P, Ouyang N, Liu X, Rigas B. NO-donating aspirin inhibits the activation of NF-kappaB in human cancer cell lines and Min mice. Carcinogenesis. 29: 390-7. PMID 18174252 DOI: 10.1093/Carcin/Bgm275 |
0.468 |
|
| 2008 |
Rigas B, Kozoni V. The novel phenylester anticancer compounds: Study of a derivative of aspirin (phoshoaspirin). International Journal of Oncology. 32: 97-100. PMID 18097547 DOI: 10.3892/Ijo.32.1.97 |
0.483 |
|
| 2007 |
McIlhatton MA, Tyler J, Burkholder S, Ruschoff J, Rigas B, Kopelovich L, Fishel R. Nitric oxide-donating aspirin derivatives suppress microsatellite instability in mismatch repair-deficient and hereditary nonpolyposis colorectal cancer cells. Cancer Research. 67: 10966-75. PMID 18006842 DOI: 10.1158/0008-5472.Can-07-2562 |
0.455 |
|
| 2007 |
Rigas B. Novel agents for cancer prevention based on nitric oxide Biochemical Society Transactions. 35: 1364-1368. PMID 17956352 DOI: 10.1042/Bst0351364 |
0.523 |
|
| 2007 |
Yang K, Lipkin M, Newmark H, Rigas B, Daroqui C, Maier S, Augenlicht L. Molecular targets of calcium and vitamin D in mouse genetic models of intestinal cancer. Nutrition Reviews. 65: S134-7. PMID 17867391 DOI: 10.1111/J.1753-4887.2007.Tb00342.X |
0.406 |
|
| 2007 |
Kozoni V, Rosenberg T, Rigas B. Development of novel agents based on nitric oxide for the control of colon cancer. Acta Pharmacologica Sinica. 28: 1429-33. PMID 17723176 DOI: 10.1111/J.1745-7254.2007.00696.X |
0.451 |
|
| 2007 |
Kashfi K, Rigas B. The mechanism of action of nitric oxide-donating aspirin. Biochemical and Biophysical Research Communications. 358: 1096-101. PMID 17512900 DOI: 10.1016/J.Bbrc.2007.05.038 |
0.428 |
|
| 2007 |
Rigas B. The use of nitric oxide-donating nonsteroidal anti-inflammatory drugs in the chemoprevention of colorectal neoplasia. Current Opinion in Gastroenterology. 23: 55-9. PMID 17133086 DOI: 10.1097/Mog.0B013E32801145B0 |
0.371 |
|
| 2006 |
Rao CV, Reddy BS, Steele VE, Wang CX, Liu X, Ouyang N, Patlolla JM, Simi B, Kopelovich L, Rigas B. Nitric oxide-releasing aspirin and indomethacin are potent inhibitors against colon cancer in azoxymethane-treated rats: effects on molecular targets. Molecular Cancer Therapeutics. 5: 1530-8. PMID 16818512 DOI: 10.1158/1535-7163.Mct-06-0061 |
0.441 |
|
| 2006 |
Zhang Z, Rigas B. NF-kappaB, inflammation and pancreatic carcinogenesis: NF-kappaB as a chemoprevention target (review). International Journal of Oncology. 29: 185-92. PMID 16773199 |
0.313 |
|
| 2006 |
Ouyang N, Williams JL, Tsioulias GJ, Gao J, Iatropoulos MJ, Kopelovich L, Kashfi K, Rigas B. Nitric oxide-donating aspirin prevents pancreatic cancer in a hamster tumor model. Cancer Research. 66: 4503-11. PMID 16618778 DOI: 10.1158/0008-5472.Can-05-3118 |
0.507 |
|
| 2006 |
Gao J, Kashfi K, Liu X, Rigas B. NO-donating aspirin induces phase II enzymes in vitro and in vivo. Carcinogenesis. 27: 803-10. PMID 16267095 DOI: 10.1093/Carcin/Bgi262 |
0.478 |
|
| 2006 |
Hundley TR, Rigas B. Nitric oxide-donating aspirin inhibits colon cancer cell growth via mitogen-activated protein kinase activation. The Journal of Pharmacology and Experimental Therapeutics. 316: 25-34. PMID 16169935 DOI: 10.1124/Jpet.105.091363 |
0.487 |
|
| 2006 |
Ouyang N, Williams JL, Rigas B. NO-donating aspirin isomers downregulate peroxisome proliferator-activated receptor (PPAR)delta expression in APC(min/+) mice proportionally to their tumor inhibitory effect: Implications for the role of PPARdelta in carcinogenesis. Carcinogenesis. 27: 232-9. PMID 16141240 DOI: 10.1093/Carcin/Bgi221 |
0.403 |
|
| 2006 |
Zhang Z, Rigas B. NF-κB, inflammation and pancreatic carcinogenesis: NF-κB as a chemoprevention target (Review) International Journal of Oncology. 29: 185-192. DOI: 10.3892/Ijo.29.1.185 |
0.423 |
|
| 2005 |
Gao J, Liu X, Rigas B. Nitric oxide-donating aspirin induces apoptosis in human colon cancer cells through induction of oxidative stress. Proceedings of the National Academy of Sciences of the United States of America. 102: 17207-12. PMID 16282376 DOI: 10.1073/Pnas.0506893102 |
0.504 |
|
| 2005 |
Spiegel A, Hundley TR, Chen J, Gao J, Ouyang N, Liu X, Go MF, Tsioulias GJ, Kashfi K, Rigas B. NO-donating aspirin inhibits both the expression and catalytic activity of inducible nitric oxide synthase in HT-29 human colon cancer cells. Biochemical Pharmacology. 70: 993-1000. PMID 16105666 DOI: 10.1016/J.Bcp.2005.06.027 |
0.445 |
|
| 2005 |
Kashfi K, Rigas B. Is COX-2 a 'collateral' target in cancer prevention? Biochemical Society Transactions. 33: 724-727. PMID 16042585 DOI: 10.1042/Bst0330724 |
0.476 |
|
| 2005 |
Kashfi K, Rigas B. Molecular targets of nitric-oxide-donating aspirin in cancer Biochemical Society Transactions. 33: 701-704. PMID 16042578 DOI: 10.1042/Bst0330701 |
0.524 |
|
| 2005 |
Kashfi K, Rigas B. Non-COX-2 targets and cancer: expanding the molecular target repertoire of chemoprevention. Biochemical Pharmacology. 70: 969-86. PMID 15949789 DOI: 10.1016/J.Bcp.2005.05.004 |
0.467 |
|
| 2005 |
Rigas B, Kashfi K. Cancer prevention: a new era beyond cyclooxygenase-2. The Journal of Pharmacology and Experimental Therapeutics. 314: 1-8. PMID 15805430 DOI: 10.1124/Jpet.104.080564 |
0.504 |
|
| 2005 |
Nath N, Labaze G, Rigas B, Kashfi K. NO-donating aspirin inhibits the growth of leukemic Jurkat cells and modulates beta-catenin expression. Biochemical and Biophysical Research Communications. 326: 93-9. PMID 15567157 DOI: 10.1016/J.Bbrc.2004.11.009 |
0.353 |
|
| 2005 |
Kashfi K, Borgo S, Williams JL, Chen J, Gao J, Glekas A, Benedini F, Del Soldato P, Rigas B. Positional isomerism markedly affects the growth inhibition of colon cancer cells by nitric oxide-donating aspirin in vitro and in vivo. The Journal of Pharmacology and Experimental Therapeutics. 312: 978-88. PMID 15528453 DOI: 10.1124/Jpet.104.075994 |
0.519 |
|
| 2005 |
Gao J, Kashfi K, Rigas B. In vitro metabolism of nitric oxide-donating aspirin: the effect of positional isomerism. The Journal of Pharmacology and Experimental Therapeutics. 312: 989-97. PMID 15528452 DOI: 10.1124/Jpet.104.076190 |
0.499 |
|
| 2004 |
Rigas B, Kashfi K. Nitric-oxide-donating NSAIDs as agents for cancer prevention. Trends in Molecular Medicine. 10: 324-30. PMID 15242680 DOI: 10.1016/J.Molmed.2004.05.004 |
0.517 |
|
| 2004 |
Yeh RK, Chen J, Williams JL, Baluch M, Hundley TR, Rosenbaum RE, Kalala S, Traganos F, Benardini F, del Soldato P, Kashfi K, Rigas B. NO-donating nonsteroidal antiinflammatory drugs (NSAIDs) inhibit colon cancer cell growth more potently than traditional NSAIDs: a general pharmacological property? Biochemical Pharmacology. 67: 2197-205. PMID 15163551 DOI: 10.1016/J.Bcp.2004.02.027 |
0.521 |
|
| 2003 |
Williams JL, Nath N, Chen J, Hundley TR, Gao J, Kopelovich L, Kashfi K, Rigas B. Growth inhibition of human colon cancer cells by nitric oxide (NO)-donating aspirin is associated with cyclooxygenase-2 induction and beta-catenin/T-cell factor signaling, nuclear factor-kappaB, and NO synthase 2 inhibition: implications for chemoprevention. Cancer Research. 63: 7613-8. PMID 14633677 |
0.349 |
|
| 2003 |
Nath N, Kashfi K, Chen J, Rigas B. Nitric oxide-donating aspirin inhibits beta-catenin/T cell factor (TCF) signaling in SW480 colon cancer cells by disrupting the nuclear beta-catenin-TCF association. Proceedings of the National Academy of Sciences of the United States of America. 100: 12584-9. PMID 14566053 DOI: 10.1073/Pnas.2134840100 |
0.367 |
|
| 2003 |
Rigas B, Kalofonos H, Lebovics E, Vagenakis AG. NO-NSAIDs and cancer: Promising novel agents Digestive and Liver Disease. 35. PMID 12846441 DOI: 10.1016/S1590-8658(03)00049-5 |
0.379 |
|
| 2003 |
Augenlicht LH, Velcich A, Klampfer L, Huang J, Corner G, Aranes M, Laboisse C, Rigas B, Lipkin M, Yang K, Shi Q, Lesser M, Heerdt B, Arango D, Yang W, et al. Application of gene expression profiling to colon cell maturation, transformation and chemoprevention. The Journal of Nutrition. 133: 2410S-2416S. PMID 12840217 DOI: 10.1093/Jn/133.7.2410S |
0.359 |
|
| 2003 |
Chen J, Nath N, Williams J, Kashifi K, Rigas B. NO-donating aspirin modulates Wnt signaling, COX-2 and NF-kappaB in human colon cancer cell lines: Implications for its effect on chemoprevention Gastroenterology. 124: A366. DOI: 10.1016/S0016-5085(03)81851-6 |
0.428 |
|
| 2003 |
Hundley T, Harley J, Lebovics E, Rigas B, Hundley T. No-donating aspirin modulates MAP kinase signaling in human colon cancer cells: Implications for its growth inhibitory effect Gastroenterology. 124: A281-A282. DOI: 10.1016/S0016-5085(03)81412-9 |
0.422 |
|
| 2003 |
Yeh R, Williams JL, Kalala S, Hundley TR, Chen J, Kashfi K, Rigas B. No-donating NSAIDs are more potent than traditional NSAIDs in inhibiting the growth of cultured human colon cancer cells Gastroenterology. 124: A132. DOI: 10.1016/S0016-5085(03)80651-0 |
0.465 |
|
| 2002 |
Rayyan Y, Williams J, Rigas B. The role of NSAIDs in the prevention of colon cancer. Cancer Investigation. 20: 1002-11. PMID 12449734 DOI: 10.1081/CNV-120005917 |
0.352 |
|
| 2002 |
Kashfi K, Ryan Y, Qiao LL, Williams JL, Chen J, Del Soldato P, Traganos F, Rigas B, Ryann Y. Nitric oxide-donating nonsteroidal anti-inflammatory drugs inhibit the growth of various cultured human cancer cells: evidence of a tissue type-independent effect. The Journal of Pharmacology and Experimental Therapeutics. 303: 1273-82. PMID 12438552 DOI: 10.1124/Jpet.102.042754 |
0.516 |
|
| 2002 |
Rigas A, Dervenis C, Giannakou N, Kozoni V, Shiff SJ, Rigas B. Selective induction of colon cancer cell apoptosis by 5-fluorouracil in humans. Cancer Investigation. 20: 657-65. PMID 12197221 DOI: 10.1081/CNV-120002491 |
0.35 |
|
| 2002 |
Rigas B, Williams JL. NO-releasing NSAIDs and colon cancer chemoprevention: a promising novel approach (Review). International Journal of Oncology. 20: 885-90. PMID 11956579 DOI: 10.3892/Ijo.20.5.885 |
0.479 |
|
| 2002 |
Kaza CS, Kashfi K, Rigas B. Colon cancer prevention with NO-releasing NSAIDs. Prostaglandins & Other Lipid Mediators. 67: 107-20. PMID 11936617 DOI: 10.1016/S0090-6980(02)00003-5 |
0.404 |
|
| 2001 |
Williams JL, Borgo S, Hasan I, Castillo E, Traganos F, Rigas B. Nitric oxide-releasing nonsteroidal anti-inflammatory drugs (NSAIDs) alter the kinetics of human colon cancer cell lines more effectively than traditional NSAIDs: Implications for colon cancer chemoprevention Cancer Research. 61: 3285-3289. PMID 11309281 |
0.362 |
|
| 2001 |
Merritt G, Aliprandis ET, Prada F, Rigas B, Kashfi K. The retinoid fenretinide inhibits proliferation and downregulates cyclooxygenase-2 gene expression in human colon adenocarcinoma cell lines. Cancer Letters. 164: 15-23. PMID 11166911 DOI: 10.1016/S0304-3835(00)00714-X |
0.323 |
|
| 2001 |
Qiao L, Rigas B, Knudson CM. Nitric oxide-releasing sulindac inhibits pancreatic cancer cell growth and induces their apoptosis Gastroenterology. 120: A666. DOI: 10.1016/S0016-5085(08)83314-8 |
0.435 |
|
| 2001 |
Williams JL, Hasan I, Borgo S, Castillo E, Traganos F, Rigas B. NO-NSAIDs alter cell kinetics in human colon cancer cell lines more efficiently than traditional NSAIDs Gastroenterology. 120: A166. DOI: 10.1016/S0016-5085(08)80819-0 |
0.445 |
|
| 2000 |
Rigas B, Shiff SJ. Is inhibition of cyclooxygenase required for the chemopreventive effect of NSAIDs in colon cancer? A model reconciling the current contradiction Medical Hypotheses. 54: 210-215. PMID 10790755 DOI: 10.1054/mehy.1999.0023 |
0.381 |
|
| 2000 |
Rigas B, Shiff SJ. Nonsteroidal anti-inflammatory drugs (NSAIDs), cyclooxygenases, and the cell cycle: Their interactions in colon cancer Advances in Experimental Medicine and Biology. 470: 119-126. PMID 10709681 DOI: 10.1007/978-1-4615-4149-3_13 |
0.301 |
|
| 1999 |
Santini DL, Rigas B, Shiff SJ. Role of diet and NSAIDs in the chemoprevention of colorectal cancer Journal of the Association For Academic Minority Physicians : the Official Publication of the Association For Academic Minority Physicians. 10: 68-76. PMID 10826012 |
0.312 |
|
| 1998 |
Cohenford MA, Rigas B. Cytologically normal cells from neoplastic cervical samples display extensive structural abnormalities on IR spectroscopy: Implications for tumor biology Proceedings of the National Academy of Sciences of the United States of America. 95: 15327-15332. PMID 9860968 DOI: 10.1073/Pnas.95.26.15327 |
0.313 |
|
| 1998 |
Qiao L, Hanif R, Sphicas E, Shiff SJ, Rigas B. Effect of aspirin on induction of apoptosis in HT-29 human colon adenocarcinoma cells Biochemical Pharmacology. 55: 53-64. PMID 9413930 DOI: 10.1016/S0006-2952(97)00400-0 |
0.303 |
|
| 1997 |
Hanif R, Qiao L, Shiff SJ, Rigas B. Curcumin, a natural plant phenolic food additive, inhibits cell proliferation and induces cell cycle changes in colon adenocarcinoma cell lines by a prostaglandin-independent pathway Journal of Laboratory and Clinical Medicine. 130: 576-584. PMID 9422331 |
0.394 |
|
| 1997 |
Shiff SJ, Rigas B. Nonsteroidal anti-inflammatory drugs and colorectal cancer: Evolving concepts of their chemopreventive actions Gastroenterology. 113: 1992-1998. PMID 9394740 DOI: 10.1016/S0016-5085(97)99999-6 |
0.399 |
|
| 1997 |
Qiao L, Shiff SJ, Rigas B. Sulindac sulfide inhibits the proliferation of colon cancer cells: Diminished expression of the proliferation markers PCNA and Ki-67 Cancer Letters. 115: 229-234. PMID 9149129 DOI: 10.1016/S0304-3835(97)04740-X |
0.304 |
|
| 1996 |
Hanif R, Pittas A, Feng Y, Koutsos MI, Qiao L, Staiano-Coico L, Shiff SI, Rigas B. Effects of nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway Biochemical Pharmacology. 52: 237-245. PMID 8694848 DOI: 10.1016/0006-2952(96)00181-5 |
0.406 |
|
| 1996 |
Bortuzzo C, Hanif R, Kashfi K, Staiano-Coico L, Shiff SJ, Rigas B. The effect of leukotrienes B and selected HETEs on the proliferation of colon cancer cells Biochimica Et Biophysica Acta - Lipids and Lipid Metabolism. 1300: 240-246. PMID 8679690 DOI: 10.1016/0005-2760(96)00003-3 |
0.331 |
|
| 1996 |
Goldberg Y, Nassif II, Pittas A, Tsai LL, Dynlacht BD, Rigas B, Shiff SJ. The anti-proliferative effect of sulindac and sulindac sulfide on HT-29 colon cancer cells: alterations in tumor suppressor and cell cycle-regulatory proteins. Oncogene. 12: 893-901. PMID 8632912 |
0.33 |
|
| 1996 |
Shiff SJ, Koutsos MI, Qiao L, Rigas B. Nonsteroidal antiinflammatory drugs inhibit the proliferation of colon adenocarcinoma cells: Effects on cell cycle and apoptosis Experimental Cell Research. 222: 179-188. PMID 8549662 DOI: 10.1006/excr.1996.0023 |
0.326 |
|
| 1995 |
Arvind P, Papavassiliou ED, Tsioulias GJ, Qiao L, Lovelace CIP, Duceman B, Rigas B. Prostaglandin E2 down-regulates the expression of HLA-DR antigen in human colon adenocarcinoma cell lines Biochemistry. 34: 5604-5609. PMID 7727422 DOI: 10.1021/Bi00016A035 |
0.353 |
|
| 1995 |
Shiff SJ, Qiao L, Tsai LL, Rigas B. Sulindac sulfide, an aspirin-like compound, inhibits proliferation, causes cell cycle quiescence, and induces apoptosis in HT-29 colon adenocarcinoma cells. The Journal of Clinical Investigation. 96: 491-503. PMID 7615821 DOI: 10.1172/JCI118060 |
0.348 |
|
| 1993 |
Rigas B, Goldman IS, Levine L. Altered eicosanoid levels in human colon cancer The Journal of Laboratory and Clinical Medicine. 122: 518-523. PMID 8228569 |
0.407 |
|
| 1990 |
Rigas B. Editorial: Oncogenes and suppressor genes: Their involvement in colon cancer Journal of Clinical Gastroenterology. 12: 494-499. PMID 2229991 |
0.308 |
|
| Show low-probability matches. |
